Celldex Therapeutics (CLDX) Stock Forecast, Price & News

Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions

Is Celldex Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Celldex Therapeutics stock.
View analyst ratings for Celldex Therapeutics or view top-rated stocks.

When is Celldex Therapeutics' next earnings date?

Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Celldex Therapeutics.

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.07. Celldex Therapeutics had a negative net margin of 1,860.46% and a negative trailing twelve-month return on equity of 21.45%.
View Celldex Therapeutics' earnings history.

When did Celldex Therapeutics' stock split? How did Celldex Therapeutics' stock split work?

Celldex Therapeutics shares reverse split on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CLDX?

5 brokerages have issued 12-month price objectives for Celldex Therapeutics' stock. Their forecasts range from $60.00 to $68.00. On average, they anticipate Celldex Therapeutics' stock price to reach $65.00 in the next twelve months. This suggests a possible upside of 116.7% from the stock's current price.
View analysts' price targets for Celldex Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the following people:

• Mr. Anthony S. Marucci M.B.A., Founder, Pres, CEO & Director (Age 60, Pay $1.18M)
• Dr. Tibor Keler, Founder, Chief Scientific Officer & Exec. VP (Age 63, Pay $748.51k)
• Mr. Sam Martin, Sr. VP, CFO, Sec. & Treasurer (Age 51, Pay $619.35k)
• Mr. Freddy A. Jimenez Esq., Sr. VP & Gen. Counsel (Age 53, Pay $579.7k) (LinkedIn Profile)
• Dr. Diane C. Young M.D., Sr. VP & Chief Medical Officer (Age 65, Pay $636k)
• Ms. Sarah Cavanaugh, Sr. VP of Corp. Affairs & Admin. (Age 47) (LinkedIn Profile)
• Patrick Till, Sr. Director of Investor Relations & Corp. Communications
• Dr. Ronald A. Pepin, Chief Bus. Officer & Sr. VP (Age 66)
• Ms. Elizabeth Crowley, Chief Product Devel. Officer & Sr. VP (Age 50) (LinkedIn Profile)
• Dr. Richard M. Wright Ph.D., Chief Commercial Officer & Sr. VP (Age 58)

Who are some of Celldex Therapeutics' key competitors?

Some companies that are related to Celldex Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), United Therapeutics (UTHR), Repligen (RGEN), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of CLDX's competitors.

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.52%), Vanguard Group Inc. (5.21%), Kynam Capital Management LP (1.61%), Dimensional Fund Advisors LP (1.27%), Northern Trust Corp (0.94%) and Charles Schwab Investment Management Inc. (0.72%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Diane C Young, Elizabeth Crowley, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin, Sarah Cavanaugh and Tibor Keler.
View institutional ownership trends for Celldex Therapeutics.

Which institutional investors are selling Celldex Therapeutics stock?

CLDX stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., BlackRock Inc., First Trust Advisors LP, Northern Trust Corp, Group One Trading L.P., Principal Financial Group Inc., Metropolitan Life Insurance Co NY, and Gyon Technologies Capital Management LP. Company insiders that have sold Celldex Therapeutics company stock in the last year include Diane C Young, Elizabeth Crowley, Samuel Bates Martin, and Sarah Cavanaugh.
View insider buying and selling activity for Celldex Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Celldex Therapeutics stock?

CLDX stock was acquired by a variety of institutional investors in the last quarter, including Kynam Capital Management LP, GMT Capital Corp, Dimensional Fund Advisors LP, Simplex Trading LLC, JPMorgan Chase & Co., Verition Fund Management LLC, Affinity Asset Advisors LLC, and Vanguard Group Inc.. Company insiders that have bought Celldex Therapeutics stock in the last two years include Anthony S Marucci, Diane C Young, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin, and Tibor Keler.
View insider buying and selling activity for Celldex Therapeutics or or view top insider-buying stocks.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $29.99.

How much money does Celldex Therapeutics make?

Celldex Therapeutics has a market capitalization of $1.40 billion and generates $4.65 million in revenue each year. The biopharmaceutical company earns $-70.51 million in net income (profit) each year or ($1.710010) on an earnings per share basis.

How many employees does Celldex Therapeutics have?

Celldex Therapeutics employs 132 workers across the globe.

When was Celldex Therapeutics founded?

Celldex Therapeutics was founded in 1983.

What is Celldex Therapeutics' official website?

The official website for Celldex Therapeutics is www.celldex.com.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at (908) 200-7500, via email at [email protected], or via fax at 908-454-1911.